Dogwood Therapeutics, Inc. (DWTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $40.52M
Last updated: Nov 17, 2026 at 4:10 PM ET
Dogwood Therapeutics, Inc. (DWTX) Statistics
Dogwood Therapeutics (DWTX) has a market cap of $40.52M and an enterprise value of $35.57M. It kept -25179.61% of revenue as net income over the last 12 months. Its share count is up 1678.11% from a year earlier.
Total Valuation
Enterprise value is 12.21% below the market cap, as cash exceeds debt.
| Market Cap | $40.52M |
|---|---|
| Enterprise Value | $35.57M |
| Latest price (Nov 17, 2026) | $1.08 |
Key Dates
The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 16, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 368.6x and 0.6x.
| P/S Ratio | 368.6x |
|---|---|
| Forward P/S | 405.2x |
| P/B Ratio | 0.6x |
Price Statistics
The stock is down 80.61% over 52 weeks and trades 20.59% below its 50-day average.
| Beta (1Y) | 0.80 |
|---|---|
| 52-Week Change | -80.61% |
| 1-Month Change | -10.74% |
| 3-Month Change | -53.25% |
| 6-Month Change | -41.62% |
| 5-Year Change | -98.90% |
| Total Return (1Y) | -80.61% |
| Total Return (3Y CAGR) | -61.18% |
| Total Return (5Y CAGR) | -62.21% |
| Return vs SPY (1Y) | -94.00% |
| Max Drawdown (1Y) | -84.90% |
| Max Drawdown (3Y) | -95.10% |
| Sharpe Ratio (1Y) | -1.93 |
| Correlation with SPY (1Y) | 0.12 |
| 50-Day Average | $1.36 |
| 200-Day Average | $1.87 |
| 52-Week Range | $0.90 to $7.04 |
| RSI (14 Days) | 40.0 |
| Average Volume (20 Days) | 104.04K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.78x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 2.78x |
|---|---|
| Quick Ratio | 2.78x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -39.26% and return on assets is -33.30% over the last 12 months.
| Return on Equity (ROE) | -39.26% |
|---|---|
| Return on Assets (ROA) | -33.30% |
| ROA (5Y Average) | -85.15% |
| ROIC (5Y Average) | -37.38% |
| Asset Turnover | 0.00x |
Scores
DWTX has an Altman Z-Score of -1.62, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.62 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $100.00K over the last 12 months.
| Revenue | $100.00K |
|---|---|
| Operating Income | -$27.86M |
| Pretax Income | -$27.63M |
| Net Income | -$25.18M |
| Reported EPS (TTM) | -$0.89 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 84.82% of the $75.61M in total assets.
| Cash and Equivalents | $4.95M |
|---|---|
| Total Debt | $0 |
| Net Cash | $4.95M |
| Net Cash Per Share | $0.14 |
| Working Capital | $3.87M |
| Shareholder Equity | $64.13M |
| Book Value Per Share | $1.88 |
| Tangible Book Value | -$5.28M |
| Total Assets | $75.61M |
| Total Liabilities | $11.47M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$16.47M |
|---|---|
| FCF Per Share | -$0.43 |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -27863.47%.
| Operating Margin | -27863.47% |
|---|---|
| Pretax Margin | -27628.11% |
| Net Margin | -25179.61% |
Dividends and Yields
DWTX does not pay a dividend.
| Buyback Yield | 0.29% |
|---|---|
| Shareholder Yield | 0.29% |
Stock Splits
The last split was a 1-for-25 reverse split on Oct 9, 2024.
| Last Split Date | Oct 9, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:25 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About DWTX
What is DWTX's market cap?
Dogwood Therapeutics has a market cap of $40.52M. Its enterprise value, which adds debt and subtracts cash, is $35.57M.
How many shares of DWTX are outstanding?
Dogwood Therapeutics has 34.13M shares outstanding. The count is up 1678.11% from a year earlier.
Does DWTX pay a dividend?
No. Dogwood Therapeutics does not pay a dividend.
How much debt does DWTX have?
Dogwood Therapeutics has $0 of total debt and $4.95M of cash and equivalents, a net cash position of $4.95M.
DWTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors